Browse News
Filter News
Found 793,572 articles
-
In a deal with Tokyo-based PRISM BioLab, Eli Lilly will gain access to the Japanese biotech’s proprietary platform to develop small molecule inhibitors of protein-protein interactions.
-
The pharma giant is paying $9 million upfront to Phenomic AI to develop targets for stroma-rich cancers, some of the hardest cancers to treat, utilizing its single-cell RNA computing platform.
-
Using electronic health records, healthcare analytics firm Truveta contends that Eli Lilly’s Mounjaro (tirzepatide) could achieve stronger and faster weight loss than Novo Nordisk’s Ozempic (semaglutide).
-
After Verve Therapeutics recently announced gene editing therapy results, the company is offering up its stock to the public and Eli Lilly. However, the stock was down 13% Wednesday on the news.
-
Deals, Dupixent and GLP-1 drug shortages
11/29/2023
This week on The Weekly we talk struggles with GLP-1 drug shortages and what that might mean for Novo and Lilly competitors; Regeneron and Sanofi positive results for Dupixent in COPD. Plus, Merck buys Caraway, Beigene's deal with Ensem, ups and downs for Flagship. -
The Swiss pharma is adopting a more streamlined strategy focusing on core therapeutic areas: cardiovascular, immunology, neuroscience and oncology, as well as renal and metabolic diseases.
-
The United States’ relatively high costs have become a political issue on both sides of the aisle. Here’s how international pharmaceutical prices stack up.
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
BioSpace spoke to analysts and players in the contract manufacturing and development organizations space to assess the challenges this year and what lies ahead in 2024.
-
QurAlis to Present Data That Show TDP-43 Pathology Drives Loss of Synaptic UNC13A Function in Neurodegenerative Diseases Including ALS and Frontotemporal Dementia
11/29/2023
QurAlis Corporation today announced it will present preclinical data showing that TDP-43 (TAR DNA-binding protein 43) pathology drives loss of synaptic UNC13A function in neurodegenerative diseases including ALS and FTD.
-
Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development
11/29/2023
Pasithea Therapeutics Corp. announced receipt of written responses to questions submitted for a Type 2 pre-Investigational New Drug Application (IND) meeting with the U.S. Food and Drug Administration (FDA) regarding clinical development plan for PAS-004.
-
Taysha Gene Therapies Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients
11/29/2023
Taysha Gene Therapies, Inc. today announced that Health Canada has authorized the protocol amendment to the ongoing REVEAL Phase 1/2 adult trial evaluating TSHA-102 that expands eligibility to include patients aged 12 and older with Rett syndrome.
-
Health Canada Grants Market Authorization for KALYDECO (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 2 Months and Older
11/29/2023
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has granted Market Authorization for the expanded use of PrKALYDECO® (ivacaftor) for the treatment of cystic fibrosis (CF) in children ages 2 months and older weighing at least 3 kg who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R or R117H.
-
Verge Genomics Will Use Modality.AI in Its ALS Phase 1b Clinical Trial of Its Lead Drug Candidate VRG50635
11/29/2023
Verge Genomics, a clinical-stage biotechnology company transforming drug discovery using artificial intelligence and human data, announced that its Phase 1b proof-of-concept (POC) study of its lead drug candidate, VRG50635, will incorporate Modality.AI, the first automated, clinically validated, multimodal system to assess speech and language patterns
-
Generation Bio Announces Strategic Reorganization to Extend Cash Runway for Development of ctLNP and iqDNA Platforms
11/29/2023
Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced a strategic reorganization to prioritize investment in the development of its cell-targeted lipid nanoparticle (ctLNP) delivery system for wholly-owned programs in extrahepatic cell types.
-
SELLAS Life Sciences Reaches Target Enrollment ex-China in Phase 3 REGAL Trial of Galinpepimut-S in Acute Myeloid Leukemia
11/29/2023
SELLAS Life Sciences Group, Inc. today announced that the target patient enrollment outside of mainland China in the ongoing Phase 3 REGAL trial of galinpepimut-S (GPS) in patients with acute myeloid leukemia (AML).
-
ASC Therapeutics Doses First Patient with ASC618 Second-Generation Gene Therapy for Hemophilia A
11/29/2023
ASC Therapeutics today announced that the first patient has been dosed in the company’s Phase I/IIa clinical trial of the lead candidate, ASC618, at the Arkansas Children’s Hospital.
-
Aperiam Bio emerges from stealth with $9 million to deliver streamlined and enhanced protein solutions
11/29/2023
OMX, Axial, KDT and Civilization Ventures join round
-
Harrow Completes Transfer of the TRIESENCE® New Drug Application
11/29/2023
Harrow (Nasdaq: HROW) today announced the completion of the transfer to Harrow of the New Drug Application (NDA) for TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL, a synthetic corticosteroid indicated for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids as well as visualization during vitrectomy.
-
Drug Discovery Services Market Size To Hold USD 75.68 Bn By 2032
11/29/2023
The global drug discovery services market size was exhibited at USD 19.37 billion in 2022 and it is expected to hit around USD 75.68 billion by 2032, growing at a CAGR of 14.6% during the forecast period from 2023 to 2032.